ALLGF News and Press, Alligator Bioscience AB

MacroGenics (MGNX) and Alligator Bioscience (ALLGF) have collaborated to expand latter's proprietary patient specific immunotherapy Neo-X-Prime with MGNX's DART and TRIDENT multi-specific platforms against two undisclosed targets. Under the collaboration, which covers activities fro...

Alligator Bioscience (ALLGF) appointed Dr. Christina Reimer as Chief Medical Officer. Most recently, she held a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen.Dr. Reimer will replace Dr. Charlotte Russel and be overall medically resp...

Alligator Bioscience recruits new Chief Medical Officer PR Newswire LUND, Sweden , Dec. 29, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. Sh...

Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 PR Newswire LUND, Sweden , Dec. 28, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial Authorization) a...

Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library LUND, Sweden , Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of a novel proprietary human synthetic antibody librar...

The FDA has signed off Alligator Bioscience's (ALLGF) Investigational new Drug for mitazalimab, a CD40 targeting antibody.The company said that the upcoming Phase 1b/2 OPTIMIZE-1 study that will start in Europe in pancreatic cancer, the IND opens up for later expansion in ...

Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab LUND, Sweden , Dec. 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalim...

Predicted therapeutic range dose levels reached in ATOR-1017 Phase I PR Newswire LUND, Sweden, Oct. 27, 2020 LUND, Sweden , Oct. 27, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety dat...

Alligator Bioscience focuses on ATOR-1017 and mitazalimab PR Newswire LUND, Sweden, Oct. 22, 2020 LUND, Sweden , Oct. 22, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the two pr...

The USPTO has issued Alligator Bioscience ( OTC:ALLGF ) a Patent No. 10,774,150, which covers compositions of matter directed to the company's bispecific drug candidate ATOR-1015. The granted patent's earliest expiry year is 2036. More news on: Alligator Bioscience AB (publ), Heal...